Skip to content
Acceleron Pharma

Investors/Media

Investors/Media

Acceleron is a Cambridge, Massachusetts-based biopharmaceutical company dedicated to the discovery and development of innovative, life-changing medicines for patients with serious and rare diseases.  Learn more about our clinical pipeline here.

Acceleron Pharma Inc. (NASDAQ: XLRN)
$36.49 - $0.41  (1.111%)
Volume: 198,016 4:00 PM ET on Nov 22, 2017

Events & Presentations

Nov 7, 2017
Acceleron Q3 Earnings Call
Listen to webcast
Sep 19, 2017
Acceleron R&D Day
Listen to webcast
View Presentation  7.1 MB
Aug 3, 2017
Acceleron Q2 Earnings Call
Jun 20, 2017
JMP Securities Life Sciences Conference

The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our product development strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, clinical trials and objectives of management and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates", "may", "project", "will", "would", "could" "should", "target", "continue", "intend" and similar expressions. There are a number of important factors that could cause Acceleron Pharma's actual results to differ materially from those indicated by such forward-looking statements, including the outcome of our preclinical testing and early clinical trials may not be predictive of success of later clinical trials and interim results of such clinical trials do not necessarily predict final results, the clinical drug development of our therapeutic product candidates involves a lengthy and expensive process, with an uncertain outcome, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our protein therapeutic product and other factors identified in the "Risk Factors" section in our filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.